pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,259 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1024Endpoints778BioPharma Dive297BioSpace215Fierce Biotech203onclive165raps74globenewswire health
therapy area
allOncology6027Rare Disease1434Cardiology1089Hematology1024Immunology1000Vaccines902Pulmonology
  • Novo vs. Lilly: Q2's cardiometabolic grudge match
    For years, Novo Nordisk and Eli Lilly have dominated the conversation surrounding obesity medicines as the duopoly competes to lead the largest pharmaceutical category in history. While dozens of c…
    Endpoints · 16d agoNeutral↗ source
  • Danske Bank discloses managerial transactions per Danish regulator on Aug 4, 2026
    Danske Bank A/S issued a notification on 4 August 2026 regarding transactions made by individuals who hold managerial responsibilities. The disclosure follows the EU Market Abuse Regulation, requi…
    globenewswire health · 16d agoRegulatoryNeutral↗ source
← prev
page 11 of 51
next →
73
fda recalls47
fda medwatch37
fda press28
899
Psychiatry & CNS712
Ophthalmology421
Endocrinology & Metabolism380
Pain373
Infectious Disease354
  • Danske Bank reports ongoing share buy-back related sales by APMH Invest
    Danske Bank A/S filed a notification on 4 August 2026 concerning transactions made by persons with managerial responsibilities. The filing, identified as notification no. 61/2026, complies with th…
    globenewswire health · 16d agoRegulatoryNeutral↗ source
  • Danske Bank reports ongoing share buy-back and manager-related share sales
    Danske Bank A/S disclosed that, as part of its share repurchase programme, APMH Invest A/S is continuously selling shares on a proportional basis. The filing notes that the transactions are made b…
    globenewswire health · 16d agoRegulatoryNeutral↗ source
  • Danske Bank files mandatory disclosure of manager transactions under EU market abuse rules
    Danske Bank A/S submitted a notification on 4 August 2026 detailing transactions made by individuals with managerial responsibilities, as required by the Danish Financial Supervisory Authority and…
    globenewswire health · 16d agoRegulatoryNeutral↗ source
  • Danske Bank reports share sale by APMH Invest under its buyback program
    On August 4, 2026 Danske Bank A/S filed a regulatory disclosure detailing a change in share ownership among its reporting parties, as required by the EU market abuse regulation. The filing states…
    globenewswire health · 16d agoRegulatoryNeutral↗ source
  • Danske Bank reports changes in shareholdings of senior staff on Aug 4, 2026
    Danske Bank A/S filed a market abuse regulation report on 4 August 2026 that records changes in share ownership by senior employees and persons closely linked to them. The filing, identified as re…
    globenewswire health · 16d agoRegulatoryNeutral↗ source
  • Danske Bank files EU market-abuse disclosure of senior staff share transactions
    Danske Bank submitted a filing on 4 August 2026 reporting changes in shareholdings by its senior employees in line with the EU market-abuse regulation. The report lists transactions carried out by…
    globenewswire health · 16d agoRegulatoryNeutral↗ source
  • FDA expands Pluvicto label, allowing most metastatic prostate cancer patients to receive the therapy
    The U.S. Food and Drug Administration has approved an expanded label for Novartis’ radiopharmaceutical Pluvicto, permitting its use together with hormone therapy in metastatic prostate cancer. The…
    Endpoints · 17d agoApprovalPositive↗ source
  • Wall Street reacts negatively to AstraZeneca-Bristol Myers merger talks, shares tumble
    A report in the Financial Times, followed by Reuters, said AstraZeneca and Bristol Myers Squibb have been discussing a possible combination in recent months. The news triggered a sharp sell-off. A…
    BioPharma Dive · 17d agoDealNegative↗ source
  • Curium to acquire Lantheus in $8 billion deal, offering $102.5 per share with upside potential
    Curium announced it will purchase radiopharmaceutical company Lantheus in a transaction valued at about $8 billion. The agreement sets the purchase price at $102.5 for each Lantheus share, and inc…
    Endpoints · 17d agoDealNeutral↗ source
  • Analysts Question Potential AstraZeneca-Bristol Myers Megamerger
    Analysts are scrutinizing a recent report that suggests AstraZeneca could merge with Bristol Myers Squibb. The proposed megamerger has sparked a series of questions about strategic fit and executio…
    Endpoints · 17d agoDealNeutral↗ source
  • BioNTech appoints Sobi head Guido Oelkers as new CEO to steer oncology shift
    BioNTech announced that Guido Oelkers, who has led the rare‑disease focused Swedish company Sobi since 2017, will become its next chief executive officer. Oelkers is slated to take over the role b…
    BioPharma Dive · 17d agoNeutral↗ source
  • Supernus and Individor to merge, creating $2 billion brain-drug company
    Supernus and Individor announced a merger that will combine their portfolios of neurological medicines. The two firms together generated about $2 billion in revenue in 2025 from roughly a dozen CN…
    BioPharma Dive · 17d agoDealPositive↗ source
  • Supernus and Indivior announce all-stock merger to create CNS-focused drugmaker
    Supernus Pharmaceuticals and Indivior Pharmaceuticals have signed an all‑stock merger agreement to combine their businesses. The new company will be dedicated to developing treatments for central…
    Endpoints · 17d agoDealPositive↗ source
  • Dash Bio secures $30 million Series A funding led by Oak HC/FT
    Dash Bio announced it has closed a $30 million Series A financing round, with Oak HC/FT serving as the lead investor. The capital will be used to expand the company’s platform that offers cloud‑sty…
    Endpoints · 17d agoDealPositive↗ source
  • Amgen reports hackers stole patient and company data in cloud breach
    Amgen disclosed on Friday that hackers have accessed and taken both company and patient information in a cyber-attack. The company said the intrusion was detected as "unauthorized activity" affect…
    Endpoints · 17d agoNegative↗ source
  • BD recalls specific lots of intraosseous needle sets over obturator removal issues
    BD announced a voluntary recall of certain lots of its intraosseous vascular access system needle sets after users reported difficulty removing the obturator after placement. The issue is linked t…
    fda medwatch · 17d agoCRLNegative↗ source
  • FDA releases new guidances on adhesive performance and skin irritation studies for transdermal generic drugs
    The U.S. Food and Drug Administration has issued two new guidances that address transdermal or topical delivery systems for generic drugs. One is a final guidance that outlines how to assess adhesi…
    raps · 17d agoRegulatoryNeutral↗ source
  • China's biotech surge highlights work-life tension for industry leaders
    China's biotechnology sector is accelerating, prompting discussions about the demanding work culture among its leaders. Shefali Agarwal, the US‑based chief executive of Sironax, said she works lon…
    Endpoints · 17d agoNeutral↗ source
  • Medical Action Industries issues correction for convenience kits with recalled Namic manifolds
    Medical Action Industries has issued a correction notice for certain convenience kits that contain Namic manifolds previously recalled by Medline. The company advises customers to immediately chec…
    fda medwatch · 17d agoCRLNegative↗ source
  • TGA seeks industry input on adopting 11 international scientific guidelines in Australia
    The Therapeutic Goods Administration announced it will consider incorporating eleven internationally recognised scientific guidelines into the Australian regulatory framework. The agency has opene…
    raps · 17d agoRegulatoryNeutral↗ source
  • FDA issues new guidances on adhesive performance and skin irritation testing for generic transdermal drugs
    The U.S. Food and Drug Administration has released two new guidances that address transdermal and topical delivery systems for generic drugs. One guidance, issued as final, focuses on how manufact…
    raps · 17d agoRegulatoryNeutral↗ source
  • BioNTech appoints Sobi's Guido Oelkers as new CEO, to start by Feb 1 2027
    BioNTech announced that Guido Oelkers, currently a leader at Swedish biotech company Sobi, will become its next chief executive officer. Oelkers is expected to take over the role no later than Feb…
    Endpoints · 17d agoNeutral↗ source
  • Medline orders correction of convenience kits containing lidocaine and bupivacaine in dextrose injection
    Medline has issued a correction for certain convenience kits that include lidocaine hydrochloride and bupivacaine hydrochloride mixed with dextrose injection. The FDA has classified this recall as…
    fda medwatch · 17d agoCRLNegative↗ source